Pulmonary fibrosis explained

Pulmonary fibrosis
Synonyms:	Interstitial pulmonary fibrosis
Field:	Pulmonology
Symptoms:	Shortness of breath, dry cough, feeling tired, weight loss, nail clubbing
Complications:	Pulmonary hypertension, respiratory failure, pneumothorax, lung cancer
Causes:	Tobacco smoking, environmental pollution, certain medications, connective tissue diseases, interstitial lung disease, unknown
Treatment:	Oxygen therapy, pulmonary rehabilitation, lung transplantation
Medication:	Pirfenidone, nintedanib
Prognosis:	Poor
Frequency:	>5 million people

Pulmonary fibrosis is a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing.^[1] Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer.^[2]

Causes include environmental pollution, certain medications, connective tissue diseases, infections, and interstitial lung diseases.^{[1] [3] [4]} However, in most cases the cause is unknown, and termed idiopathic pulmonary fibrosis.^{[1] [3]} Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests.^[1]

No cure exists and only limited treatment options are available.^[1] Treatment is directed towards efforts to improve symptoms and may include oxygen therapy and pulmonary rehabilitation.^[1] Certain medications may be used to try to slow the worsening of scarring.^[5] Lung transplantation may occasionally be an option.^[3] At least 5 million people are affected globally.^[6] Life expectancy is generally less than five years.^[3]

Signs and symptoms

Symptoms of pulmonary fibrosis are mainly:^[1]

• Shortness of breath, particularly with exertion
• Chronic dry, hacking coughing
• Fatigue and weakness
• Chest discomfort including chest pain
• Loss of appetite and rapid weight loss

Pulmonary fibrosis is suggested by a history of progressive shortness of breath (dyspnea) with exertion. Sometimes fine inspiratory crackles can be heard at the lung bases on auscultation. A chest X-ray may or may not be abnormal, but high-resolution CT will frequently demonstrate abnormalities.^[3]

Cause

Pulmonary fibrosis may be a secondary effect of other diseases. Most of these are classified as interstitial lung diseases. Examples include autoimmune disorders, viral infections and bacterial infection like tuberculosis which may cause fibrotic changes in both lung's upper or lower lobes and other microscopic injuries to the lung. However, pulmonary fibrosis can also appear without any known cause. In this case, it is termed "idiopathic". Most idiopathic cases are diagnosed as idiopathic pulmonary fibrosis. This is a diagnosis of exclusion of a characteristic set of histologic/pathologic features known as usual interstitial pneumonia (UIP). In either case, there is a growing body of evidence which points to a genetic predisposition in a subset of patients. For example, a mutation in surfactant protein C (SP-C) has been found to exist in some families with a history of pulmonary fibrosis.^[7] Autosomal dominant mutations in the TERC or TERT genes, which encode telomerase, have been identified in about 15 percent of pulmonary fibrosis patients.^[8]

Diseases and conditions that may cause pulmonary fibrosis as a secondary effect include:^{[3] [7]}

• Inhalation of environmental and occupational pollutants, such as metals^[9] in asbestosis, silicosis and exposure to certain gases. Coal miners, ship workers and sand blasters among others are at higher risk.^[10]
• Hypersensitivity pneumonitis, most often resulting from inhaling dust contaminated with bacterial, fungal, or animal products
• Cigarette smoking can increase the risk or make the illness worse.^[10] Smoking is a known cause of some types of lung fibrosis, such as the entity smoking-related interstitial fibrosis (SRIF).^[11]
• Some typical connective tissue diseases^[10] such as rheumatoid arthritis, ankylosing spondylitis, SLE and scleroderma
• Other diseases that involve connective tissue, such as sarcoidosis and granulomatosis with polyangiitis
• Infections, including COVID-19
• Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, apomorphine,^[12] and nitrofurantoin.^[13]
• Radiation therapy to the chest

Pathogenesis

Pulmonary fibrosis involves a gradual replacement of normal lung tissue with fibrotic tissue. Such scar tissue causes an irreversible decrease in oxygen diffusion capacity, and the resulting stiffness or decreased compliance makes pulmonary fibrosis a restrictive lung disease.^[14] Pulmonary fibrosis is perpetuated by aberrant wound healing, rather than chronic inflammation.^[15] It is the main cause of restrictive lung disease that is intrinsic to the lung parenchyma. In contrast, quadriplegia^[16] and kyphosis^[17] are examples of causes of restrictive lung disease that do not necessarily involve pulmonary fibrosis.

Common genes implicated in fibrosis are Transforming Growth Factor-Beta (TGF-β),^[18] Connective Tissue Growth Factor (CTGF),^[19] Epidermal Growth Factor Receptor (EGFR),^[20] Interleukin-13 (IL-13),^[21] Platelet-Derived Growth Factor (PDGF),^[22] Wnt/β-catenin signaling pathway^[23] and TNIK.^[24] Additionally, chromatin remodeler proteins impact the development of lung fibrosis, as these proteins are crucial for gene expression regulation, and their dysregulation can contribute to fibrotic disease progression.^[25]

• TGF-β is a cytokine that plays a critical role in the regulation of extracellular matrix (ECM) production and cellular differentiation.^[26] It is a potent stimulator of fibrosis, and increased TGF-β signaling is associated with the development of fibrosis in various organs.
• CTGF is a matricellular protein that is involved in ECM production and remodeling.^[26] It is up-regulated in response to TGF-β and has been implicated in the development of pulmonary fibrosis.
• EGFR is a transmembrane receptor that plays a role in cellular proliferation, differentiation, and survival. Dysregulated EGFR signaling has been implicated in the development of pulmonary fibrosis, and drugs that target EGFR have been shown to have therapeutic potential in the treatment of the disease.
• IL-13 is a cytokine that is involved in the regulation of immune responses. It has been shown to promote fibrosis in the lungs by stimulating the production of ECM proteins and the recruitment of fibroblasts to sites of tissue injury.
• PDGF is a cytokine that plays a key role in the regulation of cell proliferation and migration. It is involved in the recruitment of fibroblasts to sites of tissue injury in the lungs, and increased PDGF signaling is associated with the development and progression of pulmonary fibrosis.
• Wnt/β-catenin signaling plays a critical role in tissue repair and regeneration, and dysregulated Wnt/β-catenin signaling has been implicated in the development of pulmonary fibrosis.

Diagnosis

The diagnosis can be confirmed by lung biopsy.^[3] A video-assisted thoracoscopic surgery (VATS) under general anesthesia may be needed to obtain enough tissue to make an accurate diagnosis. This kind of biopsy involves placement of several tubes through the chest wall, one of which is used to cut off a piece of lung to send for evaluation. The removed tissue is examined histopathologically by microscopy to confirm the presence and pattern of fibrosis as well as presence of other features that may indicate a specific cause e.g. specific types of mineral dust or possible response to therapy e.g. a pattern of so-called non-specific interstitial fibrosis.

Misdiagnosis is common because, while overall pulmonary fibrosis is not rare, each individual type of pulmonary fibrosis is uncommon and the evaluation of patients with these diseases is complex and requires a multidisciplinary approach. Terminology has been standardized but difficulties still exist in their application. Even experts may disagree with the classification of some cases.^[27]

On spirometry, as a restrictive lung disease, both the FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) are reduced so the FEV1/FVC ratio is normal or even increased in contrast to obstructive lung disease where this ratio is reduced. The values for residual volume and total lung capacity are generally decreased in restrictive lung disease.^[28]

Treatment

Pulmonary fibrosis creates scar tissue. The scarring is permanent once it has developed.^[29] Slowing the progression and prevention depends on the underlying cause:

• Treatment options for idiopathic pulmonary fibrosis are very limited, since no current treatment has stopped the progression of the disease. Because of this, there is no evidence that any medications can significantly help this condition, despite ongoing research trials. Lung transplantation is the only therapeutic option available in severe cases. Having a lung transplant can improve the individual's quality of life. ^[30]
• Medications can also be considered in order to suppress the body's immune system. These types of drugs are sometimes prescribed in an attempt to slow the processes that lead to fibrosis. Some types of lung fibrosis can respond to corticosteroids, such as prednisone.^[31]
• Oxygen therapy is also a treatment option available. Their oxygen use is up to the patient on how much and how little they choose to use. The use of oxygen doesn't repair the lung damage, however it can:
  • Make breathing and exercise easier.
  • Prevent or lessen complication from low blood oxygen levels.
  • Reduce blood pressure in your heart.
  • Improve sleep and sense of well-being.

The immune system is felt to play a central role in the development of many forms of pulmonary fibrosis. The goal of treatment with immune suppressive agents such as corticosteroids is to decrease lung inflammation and subsequent scarring. Responses to treatment are variable. Those whose conditions improve with immune suppressive treatment probably do not have idiopathic pulmonary fibrosis, for idiopathic pulmonary fibrosis has no significant treatment or cure.

• Two pharmacological agents intended to prevent scarring in mild idiopathic fibrosis are pirfenidone, which reduced reductions in the 1-year rate of decline in FVC. Pirfenidone also reduced the decline in distances on the 6-minute walk test, but had no effect on respiratory symptoms.^[32] The second agent is nintedanib, which acts as an antifibrotic, mediated through the inhibition of a variety of tyrosine kinase receptors (including platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor).^[33] A randomized clinical trial showed it reduced lung-function decline and acute exacerbations.^[34]
• Anti-inflammatory agents have only limited success in reducing the fibrotic process. Some of the other types of fibrosis, such as non-specific interstitial pneumonia, may respond to immunosuppressive therapy such as corticosteroids. However, only a minority of patients respond to corticosteroids alone, so additional immunosuppressants, such as cyclophosphamide, azathioprine, methotrexate, penicillamine, and cyclosporine may be used. Colchicine has also been used with limited success. There are ongoing trials with newer drugs such as IFN-γ and mycophenolate mofetil.
• Hypersensitivity pneumonitis, a less severe form of pulmonary fibrosis, is prevented from becoming aggravated by avoiding contact with the causative material.

Prognosis

Hypoxia caused by pulmonary fibrosis can lead to pulmonary hypertension, which, in turn, can lead to heart failure of the right ventricle. Hypoxia can be prevented with oxygen supplementation.^[3]

Pulmonary fibrosis may also result in an increased risk for pulmonary emboli, which can be prevented by anticoagulants.^[3]

Epidemiology

Globally, the prevalence and incidence of pulmonary fibrosis is studied from the United States, Norway, Czech Republic, Greece, United Kingdom, Finland, and Turkey, with only two studies from Japan, and Taiwan. The issues associated with tracking the epidemiology of pulmonary fibrosis are due to the majority of these studies having participants were diagnosed with pulmonary fibrosis prior to this study. This lowers the diagnosis sensitivity, so that the prevalence and incidence has ranged from 0.7 per 100,000 in Taiwan to 63.0 per 100,000 in the United States, and the published incidence has ranged from 0.6 per 100,000 person years to 17.4 per 100,000 person years. ^[35]

The mean age of all pulmonary fibrosis patients is between 65-70 years old, making age a criterion of its own. The rarity of a person under 50 being diagnosed is because of an aging respiratory system being much more vulnerable to fibrosis and stem cell depletion.

^[36]

Incidence rate	Prevalence rate	Population	Years covered	Reference
6.8–16.3	14.0–42.7	U.S. health care claims processing system	1996–2000	Raghu et al.^[37]
8.8–17.4	27.9–63.0	Olmsted County, Minnesota	1997–2005	Fernandez Perez et al.^[38]
27.5	30.3	Males in Bernalillo County, New Mexico	1988–1990	Coultas et al.^[39]
11.5	14.5	Females

Based on these rates, pulmonary fibrosis prevalence in the United States could range from more than 29,000 to almost 132,000, based on the population in 2000 that was 18 years or older. The actual numbers may be significantly higher due to misdiagnosis. Typically, patients are in their forties and fifties when diagnosed while the incidence of idiopathic pulmonary fibrosis increases dramatically after the age of fifty. However, loss of pulmonary function is commonly ascribed to old age, heart disease or to more common lung diseases.^[40]

Following the COVID-19 pandemic, the rise in deaths for people with pulmonary fibrosis increased due to the rapid loss of pulmonary function. The consequences of COVID-19 include a large cohort of patients with both fibrosis, and progressive lung impairment. Long term follow up studies are proving long-term impairment of lung function and radiographic abnormalities suggestive of pulmonary fibrosis for patients with lung co-morbidities. ^[41]

The most common, and long-term consequence in COVID-19 patients, is pulmonary fibrosis. The biggest concerns regarding pulmonary fibrosis and the increase of respiratory follow-up following COVID-19 are supposed to be solved in the near future. Along with the respiratory follow up increases, older age with decreased lung function and/or preexisting co-morbidities, such as diabetes, cardiovascular disease, hypertension, and obesity, increase the risk of later developing fibrotic lung alterations in the COVID-19 survivors with lower exercise tolerance. Following the patients of this study determined that 40% of patients will develop a form of fibrosis of the lungs following COVID-19, and 20% of those patients will be severe instances. ^[42]

Notes and References

1. Web site: Pulmonary Fibrosis . medlineplus.gov . 20 December 2019.
2. Web site: Pulmonary fibrosis – Symptoms and causes . Mayo Clinic . 20 December 2019 . en.
3. Web site: Pulmonary Fibrosis. MedicineNet, Inc.. 26 July 2014. live. https://web.archive.org/web/20140719070851/http://www.medicinenet.com/pulmonary_fibrosis/article.htm. 19 July 2014.
4. Ahmad Alhiyari. Mousa. Ata. Fateen. Islam Alghizzawi. Mohd. Bint I Bilal. Ammara. Salih Abdulhadi. Ahmad. Yousaf. Zohaib. 2020-12-31. Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection. IDCases. 23. e01041. 10.1016/j.idcr.2020.e01041. 2214-2509. 7785952. 33425682.
5. Web site: Pulmonary fibrosis – Diagnosis and treatment – Mayo Clinic . mayoclinic.org . 20 December 2019.
6. Web site: American Thoracic Society – General Information about Pulmonary Fibrosis . thoracic.org . 20 December 2019 . 20 December 2019 . https://web.archive.org/web/20191220102922/https://www.thoracic.org/patients/lung-disease-week/2015/pulmonary-fibrosis-week/general-info.php . dead .
7. Web site: Causes. Mayo Foundation for Medical Education and Research. 26 July 2014. live. https://web.archive.org/web/20141001094930/http://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/basics/causes/con-20029091. 1 October 2014.
8. Web site: Idiopathic pulmonary fibrosis. Genetics Home Reference, United States National Library of Medicine.
9. Risk of cryptogenic fibrosing alveolitis in metal workers.. Lancet. 2000. 355. 466–467. 10841131. Hubbard R, Cooper M, Antoniak M, etal . 10.1016/S0140-6736(00)82017-6. 9202. 10418808.
10. https://www.nlm.nih.gov/medlineplus/pulmonaryfibrosis.html MedlinePlus > Pulmonary Fibrosis
11. Vehar SJ, Yadav R, Mukhopadhyay S, Nathani A, Tolle LB . Smoking-Related Interstitial Fibrosis (SRIF) in Patients Presenting With Diffuse Parenchymal Lung Disease . Am J Clin Pathol . 159. 2. 146–157. December 2022 . 36495281 . 10.1093/ajcp/aqac144 . 9891418 .
12. Web site: Not Found – BIDMC. bidmc.org. 29 April 2018. live. https://web.archive.org/web/20140316063607/http://bidmc.org/YourHealth/Conditions-AZ/Idiopathic-Pulmonary-Fibrosis.aspx?ChunkID=673487. 16 March 2014.
13. Goemaere NN, Grijm K, van Hal PT, den Bakker MA . Nitrofurantoin-induced pulmonary fibrosis: a case report . J Med Case Rep . 2 . 169 . 2008 . 18495029 . 2408600 . 10.1186/1752-1947-2-169 . free .
14. Web site: Complications. Mayo Foundation for Medical Education and Research. 26 July 2014. live. https://web.archive.org/web/20140704072229/http://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/basics/complications/con-20029091. 4 July 2014.
15. Idiopathic pulmonary fibrosis. N Engl J Med. 2001. 345. 7. 517–525. 10.1056/NEJMra003200. 16928146. Gross TJ, Hunninghake GW . 2231521.
16. Walker J, Cooney M, Norton S . Improved pulmonary function in chronic quadriplegics after pulmonary therapy and arm ergometry . Paraplegia . 27 . 4 . 278–83 . August 1989 . 2780083 . 10.1038/sc.1989.42. free .
17. http://emedicine.medscape.com/article/301760-overview eMedicine Specialties > Pulmonology > Interstitial Lung Diseases > Restrictive Lung Disease
18. Saito . Akira . Horie . Masafumi . Nagase . Takahide . August 2018 . TGF-β Signaling in Lung Health and Disease . International Journal of Molecular Sciences . en . 19 . 8 . 2460 . 10.3390/ijms19082460 . 1422-0067 . 6121238 . 30127261 . free .
19. Yang . Jibing . Velikoff . Miranda . Canalis . Ernesto . Horowitz . Jeffrey C. . Kim . Kevin K. . 2014-04-15 . Activated alveolar epithelial cells initiate fibrosis through autocrine and paracrine secretion of connective tissue growth factor . American Journal of Physiology. Lung Cellular and Molecular Physiology . en . 306 . 8 . L786–L796 . 10.1152/ajplung.00243.2013 . 1040-0605 . 3989723 . 24508728.
20. Schramm . Fabian . Schaefer . Liliana . Wygrecka . Malgorzata . January 2022 . EGFR Signaling in Lung Fibrosis . Cells . en . 11 . 6 . 986 . 10.3390/cells11060986 . 2073-4409 . 8947373 . 35326439 . free .
21. Lee . Chun Geun . Homer . Robert J. . Zhu . Zhou . Lanone . Sophie . Wang . Xiaoman . Koteliansky . Victor . Shipley . J. Michael . Gotwals . Philip . Noble . Paul . Chen . Qingsheng . Senior . Robert M. . Elias . Jack A. . 2001-09-17 . Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1 . Journal of Experimental Medicine . 194 . 6 . 809–822 . 10.1084/jem.194.6.809 . 0022-1007 . 2195954 . 11560996.
22. Andrae . Johanna . Gallini . Radiosa . Betsholtz . Christer . 2008-05-15 . Role of platelet-derived growth factors in physiology and medicine . Genes & Development . en . 22 . 10 . 1276–1312 . 10.1101/gad.1653708 . 0890-9369 . 2732412 . 18483217.
23. Liu . Jiaqi . Xiao . Qing . Xiao . Jiani . Niu . Chenxi . Li . Yuanyuan . Zhang . Xiaojun . Zhou . Zhengwei . Shu . Guang . Yin . Gang . 2022-01-03 . Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities . Signal Transduction and Targeted Therapy . en . 7 . 1 . 3 . 10.1038/s41392-021-00762-6 . 2059-3635 . 8724284 . 34980884.
24. Ren . Feng . Aliper . Alex . Chen . Jian . Zhao . Heng . Rao . Sujata . Kuppe . Christoph . Ozerov . Ivan V. . Zhang . Man . Witte . Klaus . Kruse . Chris . Aladinskiy . Vladimir . Ivanenkov . Yan . Polykovskiy . Daniil . Fu . Yanyun . Babin . Eugene . 2024-03-08 . A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models . Nature Biotechnology . en . 1–13 . 10.1038/s41587-024-02143-0 . 1546-1696. free . 38459338 .
25. Trejo-Villegas . Octavio A. . Heijink . Irene H. . Ávila-Moreno . Federico . 2024-06-22 . Preclinical evidence in the assembly of mammalian SWI/SNF complexes: Epigenetic insights and clinical perspectives in human lung disease therapy . Molecular Therapy . 10.1016/j.ymthe.2024.06.026 . 1525-0016.
26. Todd . Nevins W. . Luzina . Irina G. . Atamas . Sergei P. . 2012-07-23 . Molecular and cellular mechanisms of pulmonary fibrosis . Fibrogenesis & Tissue Repair . 5 . 1 . 11 . 10.1186/1755-1536-5-11 . 1755-1536 . 3443459 . 22824096 . free .
27. Web site: Tests and diagnosis. Mayo Foundation for Medical Education and Research. 26 July 2014. live. https://web.archive.org/web/20140704062802/http://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/basics/tests-diagnosis/con-20029091. 4 July 2014.
28. Web site: spirXpert.com . live . https://web.archive.org/web/20100128062701/http://www.spirxpert.com/characteristic6.htm . 28 January 2010 .
29. Web site: Pulmonary Fibrosis . live . https://web.archive.org/web/20140719070851/http://www.medicinenet.com/pulmonary_fibrosis/article.htm . 19 July 2014 . 26 July 2014 . MedicineNet, Inc..
30. Web site: Pulmonary fibrosis – Diagnosis and treatment – Mayo Clinic . 20 December 2019 . mayoclinic.org.
31. Web site: Pulmonary Fibrosis . live . https://web.archive.org/web/20140719070851/http://www.medicinenet.com/pulmonary_fibrosis/article.htm . 19 July 2014 . 26 July 2014 . MedicineNet, Inc..
32. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.. NEJM. May 2014. 370. 2083–2092. 10.1056/NEJMoa1402582. King TE Jr . Bradford WZ . Castro-Bernardini S . 24836312. 22. etal.
33. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011. 365. 12. 1079–1087 . Richeldi L, Costabel U, Selman M, etal . 10.1056/nejmoa1103690. 21992121. free.
34. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. May 2014. 370. 22. 2071–2082. 10.1056/NEJMoa1402584. Richeldi L, du Bois RM, Raghu G, etal. 24836310. 11365/974374. free.
35. Ley . Brett . Epidemiology of Idiopathic Pulmonary Fibrosis . Clinical Epidemiology . 2013 . 5 . 483–492 . 10.2147/CLEP.S54815 . free . 24348069 . 3848422 .
36. Vasarmidi. Eirini. Tsitoura. Eliza. Spandidos. Demetrios A.. Tzanakis. Nikolaos. Antoniou. Katerina M.. September 2020. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Experimental and Therapeutic Medicine. 20. 3. 2557–2560. 10.3892/etm.2020.8980. 1792-0981. 7401793. 32765748.
37. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2006;174:810-6.
38. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH. Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis: A Population-Based Study. Chest. Jan 2010;137:129-37.
39. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The Epidemiology of Interstitial Lung Diseases. Am J Respir Crit Care Med. Oct 1994;150(4):967-72. cited by Michaelson JE, Aguayo SM, Roman J. Idiopathic Pulmonary Fibrosis: A Practical Approach for Diagnosis and Management. Chest. Sept 2000;118:788-94.
40. 39
41. 40
42. 41